The latest GINA strategy is the 2026 edition, published May 5, 2026, with its Summary Guide published in July. Its central message is continuity with more detailed pathways: asthma treatment for adults, adolescents and children aged 6–11 should include an inhaled corticosteroid (ICS), while adults and adolescents are generally steered toward Track 1, using low-dose ICS-formoterol as the reliever and, at higher steps, as both daily maintenance and reliever therapy (MART). The 2026 update also gives clinicians new acute-care flowcharts, revised oxygen thresholds and more conservative short-acting beta2-agonist (SABA) dosing. These are points to discuss with a qualified clinician, not instructions to start, stop or change an inhaler yourself.
The 2026 GINA update in plain language
The Global Initiative for Asthma (GINA) updates its strategy each year after its scientific committee reviews new literature. The current edition identified here is the 2026 GINA Strategy Report, dated May 5, 2026. The accompanying Summary Guide followed in July 2026 and is written for healthcare professionals and policy-makers.
As an Amazon Associate I earn from qualifying purchases.
For someone living with asthma, the practical change is not a wholesale replacement of treatment. It is a clearer preference for anti-inflammatory reliever therapy, more explicit age-specific options, and a more detailed approach to an acute attack. Local regulatory approvals, available inhalers and a person’s other medical conditions still determine what a clinician can prescribe.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
What changed in acute asthma care
GINA’s 2026 “What’s New” document adds four flowcharts for assessing and treating acute asthma in primary-care, emergency-department and other acute-care settings. They cover adults and adolescents, children aged 6–11, and children aged 5 years and younger. The flowcharts are designed for trained healthcare staff; they are not a home dosing schedule.
#1 Best Overall
Validated severity scoring for children
For children, the update emphasizes use of a validated severity score rather than relying on a single observation. The Pediatric Respiratory Assessment Measure (PRAM) is given as an example. A score is interpreted alongside examination findings, oxygen saturation, response to treatment and the child’s history. Parents should not attempt to calculate a score to decide whether to seek urgent care.
Revised oxygen thresholds and targets
The 2026 flowcharts state that supplemental oxygen is not recommended unless oxygen saturation is below 92% in the specified acute-care pathways. When oxygen is used, the target is 92–95% for adults, adolescents and children aged 6–11. For children aged 5 and younger with acute wheeze or a severe exacerbation, the stated target is at least 92%.
GINA also warns that pulse oximeters can overestimate saturation in people with hypoxemia and dark skin. Altitude may require a different interpretation of readings and targets. A home oximeter therefore cannot replace a clinical assessment, particularly when breathing is worsening, speech is difficult or the person appears exhausted.
The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →More conservative SABA dosing
The 2026 overview recommends more conservative SABA doses in acute care than some earlier practice patterns. GINA highlights concern about overtreatment and toxicity, including lactic acidosis caused by high beta2-agonist exposure. Lactic acidosis can produce rapid breathing and be mistaken for worsening bronchospasm, potentially leading to still more unnecessary SABA. The dose and delivery method must be selected and monitored by the treating team.
ICS-formoterol for selected mild exacerbations
For adults, adolescents and children aged 6–11 who present to primary care or an emergency department with a mild exacerbation, the update adds ICS-formoterol as an option. This does not mean a person should substitute one inhaler for another or increase use without a written plan. The recommendation applies to clinician-managed acute care and depends on the product’s approval, strength and the patient’s prescribed regimen.
Anaphylaxis takes priority
When asthma symptoms occur with anaphylaxis, GINA says epinephrine should be given first. Wheeze during a severe allergic reaction can be life-threatening anaphylaxis rather than an isolated asthma flare. Emergency services should be contacted immediately; an asthma reliever must not delay epinephrine when anaphylaxis is suspected.
What remains central in everyday treatment
ICS-containing treatment is the foundation
GINA says adults, adolescents and children aged 6–11 should receive treatment that includes an inhaled corticosteroid. ICS reduces airway inflammation, which is why relying only on a quick-relief bronchodilator is not the preferred routine strategy. Ask your prescriber which part of your regimen supplies the ICS and when it should be taken. Do not stop a controller because symptoms have temporarily improved.
Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Clear out junk files and repair common Windows errorsFree Scan →Adults and adolescents: why Track 1 is preferred
For people aged 12 and older, GINA generally prefers Track 1. At Steps 1–2, low-dose ICS-formoterol is used as the reliever. At Steps 3–4, the same combination can be used as both scheduled maintenance and relief; this is called maintenance-and-reliever therapy (MART).
GINA prefers Track 1 because the guide describes a lower risk of severe exacerbations and a simpler arrangement than Track 2. The strategy is not claiming that one inhaler suits every person. Formoterol-containing products must be licensed for the intended use, and availability differs by country. Kidney, heart, pregnancy, interaction and other clinical considerations also belong in the prescribing decision.
Track 2 remains an alternative
Track 2 uses a different controller-and-reliever arrangement, with a separate reliever rather than the Track 1 ICS-formoterol approach. It may be considered when an appropriate ICS-formoterol product is unavailable, not licensed for the needed step, unsuitable for the individual or not chosen after shared decision-making. The exact controller, reliever and dosing schedule are determined locally and are not interchangeable with Track 1 instructions.
| Question | Track 1 | Track 2 |
|---|---|---|
| Reliever | Low-dose ICS-formoterol at Steps 1–2; the reliever contains an anti-inflammatory ICS. | A separate reliever in a clinician-selected regimen; the specific product is not fixed by the summary guide. |
| Maintenance and relief | At Steps 3–4, the same ICS-formoterol inhaler can provide maintenance and relief (MART). | Controller and reliever are arranged separately; the exact schedule depends on the prescribed option. |
| Why GINA ranks it | Preferred because the guide says it reduces severe-exacerbation risk and is simpler. | Alternative when Track 1 is unavailable, unlicensed, unsuitable or not selected. |
| What can change the choice | Local approval, supply, inhaler technique, adherence, comorbidities and clinician assessment. | The same factors, plus whether the person can reliably take the separate controller as prescribed. |
Children follow a distinct pathway
The Summary Guide separates adults and adolescents aged 12 or older from children aged 6–11. It directs readers to the full strategy for detailed recommendations for children aged 5 and younger, so a younger child’s plan should not be inferred from the older age groups.
| Age group | What the 2026 material establishes | Important qualification |
|---|---|---|
| Adults and adolescents 12+ | Track 1 is preferred: low-dose ICS-formoterol as reliever at Steps 1–2 and MART at Steps 3–4. | Licensing, supply and individual suitability vary. |
| Children 6–11 | Step 1 includes as-needed low-dose ICS-formoterol or an ICS-SABA option; higher steps use daily ICS-containing treatment. A child needing Step 4 may warrant review by a pediatric asthma expert. | The child-specific dose and device must be prescribed and taught by the clinical team. |
| Children 5 and younger | The acute-care flowchart includes this age group, including a target of at least 92% when oxygen is used for acute wheeze or severe exacerbation. | The Summary Guide’s detailed routine-treatment scope is 6–11; use the full report and pediatric advice for younger children. |
What the update means for your next asthma review
Bring the complete picture, not just a symptom count
GINA’s management cycle considers daytime and nighttime symptoms, exacerbations, side effects, other illnesses, lung function, inhaler technique, adherence, preferences and goals. A person who reports frequent symptoms may need a different intervention from someone whose symptoms are controlled but who has had a dangerous flare. Ask the clinician to review these factors together before deciding whether treatment should change.
Have your technique checked
Incorrect inhaler technique can make an effective prescription appear ineffective. At a visit, demonstrate how you prepare the device, inhale, hold your breath and clean or replace it according to its instructions. Ask whether a spacer is appropriate for your specific inhaler. Do not buy or add a device solely because it is mentioned online; compatibility and technique teaching matter.
Review adherence without blame
Tell the clinician if cost, side effects, schedule, forgetfulness, stigma or difficulty using the device makes regular ICS use hard. A simpler regimen may help some people, which is one reason GINA values Track 1’s single-inhaler approach when it is suitable. The solution might instead be education, a different device, reminders, treatment of side effects or help obtaining an approved medicine.
Update the written action plan
An action plan should state your usual medicines, what changes count as deterioration, when to use the prescribed reliever, when to contact a clinician and when to seek emergency help. Ask whether the plan matches your current Track, age group and inhalers. Never copy an internet dosing schedule into it.
Free tools Windows power users keep installed
One-click scans. No signup required.
Discuss exposures and risk factors
GINA identifies tobacco smoke, vaping, air pollution, allergens and inadequate ICS use among relevant exposures or risks. Explain where and when symptoms occur, including at work, during exercise, around pets or after respiratory infections. Reducing an avoidable exposure can complement medication, but it does not replace anti-inflammatory treatment when that treatment is prescribed.
Does GINA still recommend a rescue inhaler?
“Rescue inhaler” is a patient term rather than a single GINA category. GINA still includes reliever treatment, but its preferred adult and adolescent Track 1 uses ICS-formoterol, which provides rapid bronchodilation together with an anti-inflammatory corticosteroid. At higher steps, that same inhaler is also the maintenance inhaler in MART.
Some people will use Track 2 with a separate reliever, and children have age-specific options. Whether your reliever is appropriate depends on the treatment track, product license and written plan. Do not discard a prescribed inhaler or switch to an ICS-formoterol product without a clinician confirming the change.
When symptoms are urgent
Seek emergency help for severe breathlessness, inability to speak normally, bluish or grey lips, confusion, collapse, rapidly worsening symptoms or poor response to the prescribed action plan. If asthma symptoms accompany signs of anaphylaxis—such as swelling of the tongue or throat, widespread hives, faintness or sudden breathing difficulty—use prescribed epinephrine as directed and call emergency services. These warning signs require urgent assessment regardless of which GINA track you use.
Windows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallOutdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchWhy the update matters globally
The 2026 Summary Guide describes asthma as “a serious global health problem.” It estimates that approximately 300 million people worldwide have asthma and that approximately 96% of people who die from asthma are in low-income or middle-income countries. GINA presents these figures in its July 2026 guide; the passage does not identify the original estimate or its year, so they should be understood as figures reported by GINA rather than a newly verified independent survey.
The emphasis on ICS access, simple regimens, oxygen interpretation and conservative acute-care dosing has particular importance where medicines, trained staff and reliable monitoring are limited. Availability and national regulations still determine what can actually be delivered.
How to read the official 2026 material
- Use the 2026 Strategy Report page for the edition date and official publication information.
- Use the 2026 Summary Guide PDF for the clinician-facing overview of routine management and age groups.
- Use the “What’s New” report for the acute-care changes, oxygen thresholds, severity scoring and SABA discussion.
- Learn about GINA’s annual program on its official program page, and check for a newer edition before relying on this year’s details.
- The publication page for the 2026 Summary Guide provides official access and edition information. GINA states that commercial or promotional reuse of its report and guides requires approval.
Bottom line
GINA’s 2026 strategy keeps ICS-containing treatment at the center, prefers ICS-formoterol Track 1 for most adults and adolescents when locally approved and suitable, and gives clinicians more precise tools for acute attacks. The safest way to apply it is to review your inhaler technique, adherence, triggers, action plan and treatment track with your clinician rather than making an independent medication change.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
